Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

387
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
387
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

310
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
310
Inhaled Medications01:23

Inhaled Medications

389
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
389
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

324
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
324
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

583
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
583
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.5K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical phenotypes in α<sub>1</sub>-antitrypsin deficiency: a cluster analysis on EARCO data.

ERJ open research·2026
Same author

Risk of Mortality and Cardiovascular Events in Patients with Chronic Obstructive Pulmonary Disease Treated with Azithromycin, Roxithromycin, Clarithromycin and Amoxicillin in Primary and Secondary Care.

Biomedicines·2026
Same author

Severe Hospitalization-Requiring Viral Infection With Influenza or COVID-19: Metabolic Pathway Analysis.

Open forum infectious diseases·2026
Same author

Collagen- and elastin-derived biomarkers and acute severe exacerbations in COPD: a sub study of the CORTICO-COP trial.

Scientific reports·2026
Same author

Paired serological testing of rubella IgG: monitoring antibody stability over time.

Infectious diseases (London, England)·2026
Same author

Plasma Albumin Changes During Admission for Bloodstream Infection as Prognostic Predictors After Discharge-A Population-Based Cohort Study.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Sep 11, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K

Inhaled Corticosteroids and Risk of Staphylococcus aureus Isolation in Bronchiectasis: A Register-Based Cohort Study.

Andrea Arlund Filipsen1, Karen Hougaard Frost1, Josefin Eklöf1

  • 1Copenhagen Respiratory Research, Department of Medicine, Herlev and Gentofte Hospital, University of Copenhagen, 2900 Hellerup, Denmark.

Journal of Clinical Medicine
|August 14, 2025
PubMed
Summary

High-dose inhaled corticosteroids (ICS) increase the risk of Staphylococcus aureus (S. aureus) isolation in non-cystic fibrosis bronchiectasis (BE) patients. Use ICS cautiously in BE patients due to this association.

Keywords:
ICS useIPTWS. aureusStaphylococcus aureusbronchiectasiscohort studycox regressioninfectioninhaled corticosteroidsnon-cystic fibrosis bronchiectasis

More Related Videos

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

663
Studying Microbial Communities In Vivo: A Model of Host-mediated Interaction Between Candida Albicans and Pseudomonas Aeruginosa in the Airways
06:43

Studying Microbial Communities In Vivo: A Model of Host-mediated Interaction Between Candida Albicans and Pseudomonas Aeruginosa in the Airways

Published on: January 13, 2016

9.0K

Related Experiment Videos

Last Updated: Sep 11, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K
Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

663
Studying Microbial Communities In Vivo: A Model of Host-mediated Interaction Between Candida Albicans and Pseudomonas Aeruginosa in the Airways
06:43

Studying Microbial Communities In Vivo: A Model of Host-mediated Interaction Between Candida Albicans and Pseudomonas Aeruginosa in the Airways

Published on: January 13, 2016

9.0K

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Pharmacology

Background:

  • Non-cystic fibrosis bronchiectasis (BE) is a chronic airway disease with rising prevalence and mortality.
  • Inhaled corticosteroids (ICS) are commonly used in BE despite limited evidence for lung function benefits.
  • The potential link between ICS use and Staphylococcus aureus (S. aureus) infections in BE is not well understood.

Purpose of the Study:

  • To investigate the association between pre-diagnosis ICS use at varying doses and the risk of S. aureus isolation in BE patients.
  • To determine if ICS dose influences the risk of S. aureus isolation in this population.

Main Methods:

  • A national register-based cohort study of Danish BE patients diagnosed between 2001-2018.
  • ICS exposure categorized into none, low, moderate, and high doses based on prescriptions redeemed 365 days prior to diagnosis.
  • Cause-specific Cox proportional hazards regression and inverse probability of treatment weighted (IPTW) models were employed.

Main Results:

  • High-dose ICS use was significantly associated with an increased risk of S. aureus isolation (HR 3.81).
  • No significant association was found for low or moderate ICS doses (HR 1.22 and 1.24, respectively).
  • Sensitivity analysis using IPTW confirmed these findings.

Conclusions:

  • High-dose ICS treatment is linked to a higher risk of S. aureus isolation in patients with non-cystic fibrosis bronchiectasis.
  • Caution is advised when prescribing ICS, particularly at high doses, for BE management.
  • Further research may explore mechanisms underlying this association.